secwatch.observer — SEC 8-K summary
======================================

Issuer:     STAAR SURGICAL CO (STAA)
CIK:        0000718937
Form:       8-K
Filed at:   2026-09-09T21:37:25+00:00
Accession:  0001193125-26-386662
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

STAAR Surgical appoints former CEO David Bailey as Chief Commercial Officer
---------------------------------------------------------------------------

- David Bailey named Chief Commercial Officer effective Sept 8, 2026; joins executive committee, reports to CEO Warren Foust.
- Bailey was STAAR CEO 2001-2008 and President Intl Ops 2008-2011; raised $60M+, secured 2005 FDA ICL approval, led Asia launches.
- Compensation: CHF 462,825 (~$575K) base, 60% target bonus, $850K RSU grant, $1.4M LTI award (50% options/50% RSUs).
- Return aims to accelerate EVO ICL growth as laser refractive volumes decline globally; expansion into South/Southeast Asia, South America, Africa.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/718937/000119312526386662/0001193125-26-386662-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/718937/000119312526386662/staa-20260909.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-386662

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer